Paul LaViolette
Investing Profile
SV Health Investors thesis
Rondo Therapeutics is a biopharmaceutical company breaking new ground in cancer therapy. The company’s mission is to advance bispecific antibody therapies that address unmet needs in the treatment of solid tumors. Rondo is developing a new class of bispecific antibodies designed to harness the immune system to target and eliminate tumors with enhanced safety. Rondo Therapeutics is supported by Canaan Partners, Red Tree Venture Capital, Johnson & Johnson, SV Health Investors, and Novo Holdings. In addition to RNDO-564, the company’s pipeline includes immune-engaging bispecifics for a range of s
Sector and stage focus
- Seed: Medical Devices, BioTech
- Series B: BioTech, Medical Devices
- Series A: Medical Devices, BioTech
- general: Boston / New England
Recent investments by Paul LaViolette
Paul LaViolette has 2 named past investments in the public record. The most recent:
| Company | Stage | Date | Round size |
|---|---|---|---|
| CardioKinetix | Series F | Dec 2014 | $50M |
| CSA Medical | Series C | Dec 2013 | $16M |
Frequent co-investors
Paul LaViolette has co-invested with: Jeani Delagardelle, Casey Tansey, Tara Butler.
Is Paul LaViolette a fit for your round?
Upload your pitch deck and see whether Paul LaViolette appears in your top 20 matches.
Find investors for your deck